Theranostics at a Crossroads: Y-90 Radioembolization Injuries and the Fight for Accountability in 2026

For decades, the promise of theranostics—combining diagnostic imaging with targeted therapy—has driven innovation in oncology. Our past records show that leaders like Dr. John R. Reddington, a founding figure at Nova TheraNostics, brought deep expertise from Sirtex Medical (pioneer of yttrium-90 microspheres) and helped shape the virtual, lean operational model we still follow. But with innovation comes risk. Since 2019, the FDA has logged hundreds of adverse event reports tied to Y-90 radioembolization—ranging from radiation-induced liver disease to non-target embolization causing permanent organ damage. As a firm dedicated to safety analysis and legal evaluation, we track these developments closely. The landscape today is defined by a growing mass tort: the Y-90 Microsphere MDL (MDL 3023), now consolidating over 1,200 plaintiff cases. Victims of faulty delivery systems or inadequate shielding are fighting for compensation. This article examines the medical realities, the class action mechanics, and what you need to know if you or a loved one suffered a catastrophic adverse event after Y-30 treatment.

Understanding the Risks of Yttrium-90 Radioembolization: The Sirtex Legacy and FDA Advisories

Yttrium-90 radioembolization (also called SIRT—selective internal radiation therapy) involves infusing millions of microscopic radioactive beads into hepatic arteries to irradiate liver tumors. When performed correctly, it spares healthy tissue. However, procedural errors—miscalculated dosimetry, mispositioned catheters, or defective microspheres—can cause severe complications. The FDA has issued multiple safety communications since 2020, citing leaks of Y-90 from faulty delivery systems and incidents of radiation necrosis in the gallbladder, duodenum, or pancreas. Sirtex Medical, the manufacturer of SIR-Spheres, faced a class action in Australia and later a US MDL after reports that pre-treatment calibrations were inadequate. Our team, drawing on radiological backgrounds similar to Dr. Reddington’s, has reviewed autopsy data showing that some patients received doses 300% higher than intended. The result? Acute radiation hepatitis, irreversible fibrosis, and in some cases, accelerated liver failure.

"Nova TheraNostics is managed by an experienced group of industry veterans with an extensive history of start-up, big pharma, scientific, and radiologic experience."
— Nova TheraNostics About Us (see also archived reference)

We now operate at the intersection of medical monitoring and litigation support. Each year, roughly 5,000 patients undergo Y-90 procedures in the US. Of those, an estimated 15–20% experience a reportable adverse event. While not all result in lasting harm, the subset that does—especially in cases of off-target deposition—can require decades of follow-up care. The FDA’s Center for Devices and Radiological Health has flagged the failure to use proper lung-shunt fraction calculations as a contributing factor. In 2023, the agency added a black-box warning to the device labeling for SIR-Spheres, but by then thousands of patients had already been treated under outdated protocols.

Legal Implications: MDL 3023 and the Statute of Limitations for Theranostics-Related Injuries

This legal context is crucial for anyone harmed before the labeling changes. MDL 3023, formally In re: Y-90 Microsphere Products Liability Litigation, is centralized in the Northern District of Texas. The MDL consolidates claims that Sirtex and other manufacturers failed to warn about the risk of extrahepatic migration of radioactive beads. Plaintiffs allege design defects and manufacturing errors in the delivery catheter and calibration software. The first bellwether trial is scheduled for late 2026. If you had a Y-90 procedure more than two years ago, the statute of limitations may already be running—it varies by state, from one to six years. Missing the deadline eliminates your ability to join any class action or individual lawsuit. The mass tort structure allows for group discovery and settlement pools, but each plaintiff must prove causation and damages.

Key terms every potential plaintiff should know:

• MDL – Multi-District Litigation, a mechanism that coordinates pre-trial proceedings for similar cases.
• Mass Tort – Different from a class action; each plaintiff retains an individual claim, but common issues are handled together.
• Statute of limitations – The time window to file suit; typically begins at diagnosis of the injury, not the procedure date.
• Settlement – A negotiated resolution; in MDL 3023, global settlement talks are ongoing but no final agreement has been reached.
• Litigation – The formal process of taking legal action; cases can be tried individually or as part of the MDL.

Currently, the settlement discussions are being stalled by arguments over the sufficiency of pre-market testing. The FDA’s own adverse event database (FAERS) shows 2,300+ reports for SIR-Spheres and TheraSphere (the other major Y-90 device) since 2015. Compensation amounts in comparable medical device MDLs have ranged from $150,000 to over $2 million per plaintiff, depending on injury severity, lost wages, and medical expenses. To participate, you must have contemporaneous medical records documenting your adverse event—ideally with radiology reports showing non-target embolization.

Step-by-Step Guide: What Affected Patients Should Do Now

If you or a family member experienced serious complications after Y-90 radioembolization, do not wait. Follow these steps:

1. Collect all procedure records – Include pre-treatment angiograms, dosimetry calculations, and the specific lot numbers of microspheres used.
2. Obtain a current imaging study – CT or MRI to document any residual damage such as portal hypertension or bile duct strictures.
3. Document ongoing symptoms – Fatigue, jaundice, ascites, or abdominal pain persisting beyond 3 months post-procedure.
4. Contact a mass tort attorney – Look for firms experienced in MDL 3023; many offer free consultations and work on contingency.
5. Verify your state’s statute of limitations – Use the table below as a guide, but confirm with counsel.

Note: The “discovery rule” means the clock starts when you knew or should have known the injury was caused by the Y-90 procedure, not on the treatment date. However, courts have set outer limits—in some states, even with the discovery rule, you cannot file more than 4–6 years after the procedure.

Conclusion & Free Case Review

The convergence of our radiologic heritage—born from founders like Dr. Reddington—with today’s Y-90 litigation creates a powerful moment for patient advocacy. We’ve seen how adverse events can devastate lives, and we believe that those harmed by defective theranostics devices deserve full compensation. Whether through an MDL settlement or a trial verdict, the window to act is narrowing. Don’t let the statute of limitations expire. Contact our partner network today to learn if you qualify for no-obligation legal representation. Your health records and a single call could start the process of holding manufacturers accountable.